|
|
Article: Vanguard Equity Research Corp Announces Investment Opinion: Vanguard Equity Research Corp Initiates Coverage on Skystar Bio-Pharmaceutical with a Buy Rating and a $2.75 Price Target.
- Article from:
- Business Wire
- Article date:
- February 27, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO -- Vanguard Equity Research Corp (VERC), a leading independent equity research firm, announced today that it has initiated coverage on Skystar Bio-Pharmaceutical Company (OTCBB:SKBI). VERC analyst, Michael Anderegg, CFA, issued a Buy rating with a 12-month price target of $2.75 in the comprehensive research report. The complimentary 30 page report is available on VERC's website at www.vanguarderc.com as well as on leading financial portals.
Skystar Bio-Pharmaceutical Company is a China-based producer and distributor of vaccines, microorganisms and 100% organic herbal additives to cure and prevent disease in poultry, livestock, birds and pets.
...